REAL-WORLD EVIDENCE
Capture Real-World Evidence
Tap into consented,
recontactable cohorts
Our approach
Filling evidence gaps
Inspire’s patient cohorts
Inspire’s Real-World Evidence Platform is powered by existing consented and recontactable cohorts from the Inspire patient community. This includes over 3,000 conditions across rare disease, chronic disease and cancer.
1 Million+ oncology/solid tumor
Lung, Breast, Cervical, Thyroid, Ovarian, Bladder, Brain, Prostate, Colorectal, Liver, Head & Neck, Pancreatic, Melanoma, Kidney, Gastric, Soft Tissue Sarcoma, PNET
800K rare disease
Ehlers Danlos, Neurofibromatosis, Interstitial Cystits, Nephrotic / FSGS, Mast Cell Disease, Charcot-Marie Tooth, Tuberous Sclerosis, Wilson’s Disease, Sickle Cell Anemia, Leukodystrophy, Amyloidosis, Cystic Fibrosis, Cushing’s Disease
850 Autoimmune conditions
Psoriasis, Fibromyalgia, Eczema, Rheumatoid Arthritis, Scleroderma (SS), Psoriatic Arthritis, Lupus, Crohn’s Disease, Ulcerative Colitis, Celiac Disease, Sjogren’s
100K Oncology/Hematology
Lymphoma, Leukemia, Non-Hodgkins Lymph, Multiple Myeloma, Chr. Lymph. Leukemia (CLL), Acute Myeloid Leukemia (AML), Chr. Myeloid Leukemia (CML), Myelofibrosis
Inspire Virtual Registry
Some examples of our work
Pfizer had been unable for years to find patients to test a hypothesis linking rare genetic drivers to increasing cancer survivability. Inspire was able to identify and recruit more than 120 patients for genetic sequencing.
Inspire helped shed light on disease burden and unmet needs for patients with 2 rare neuromuscular conditions.
Inspire researchers accurately identified adverse drug reactions in cancer patients by using Inspire data, 7 months ahead of FDA reporting of the same adverse reactions.
Our research
Featured projects
Social media posts reveal the true impact of multiple myeloma on patients and caregivers
Contact us to learn more
"*" indicates required fields